Cargando…

Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis

Detalles Bibliográficos
Autores principales:	Garcia Whitlock, Anna E., Titchenell, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296225/ https://www.ncbi.nlm.nih.gov/pubmed/32220558 http://dx.doi.org/10.1016/j.jcmgh.2020.03.001

Ejemplares similares

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Nature or Nurture? The Answer Is “Both” in Nonalcoholic Steatohepatitis
por: Carr, Rotonya M.
Publicado: (2020)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey
por: Alves, Venancio Avancini Ferreira, et al.
Publicado: (2016)

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
por: Zhang, Yao, et al.
Publicado: (2022)

Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis
por: Jeong, Jain, et al.
Publicado: (2020)

Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
por: Tincopa, Monica A.
Publicado: (2020)

The Role of Natural Killer Cells in Nonalcoholic Steatohepatitis: An Ongoing Debate
por: Jiang, Xiaojun, et al.
Publicado: (2021)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
por: Xu, Gang, et al.
Publicado: (2021)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males
por: Hendrikx, Tim, et al.
Publicado: (2017)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

RB in glutamine metabolism
por: Clem, Brian
Publicado: (2014)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis?
por: Hinz, Kaitlyn, et al.
Publicado: (2023)

Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis
por: Wang, Leijie, et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis
por: Katayama, Akihiro, et al.
Publicado: (2015)

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
por: Finck, Brian N.
Publicado: (2018)

Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Kim, Tae Hyung, et al.
Publicado: (2021)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
por: Castillo-Castro, Carolina, et al.
Publicado: (2021)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n0uuskfh8ss881l83pj7vncfe3